Drug intelligence / Profile preview

MFA-021

Development stage: Preclinical
Lead developer: MediMabBio
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MFA-021 is an investigational antibody fusion protein developed by MediMabBio Co., Ltd. It acts as a dual-mechanism drug, functioning as a Glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) agonist and an Interleukin-15 (IL-15) inhibitor. This therapeutic approach is being explored for the treatment of neoplasms.

Targets

TNFRSF18 (GITR)IL15 (Interleukin 15)

Beyond the preview

Go deeper on MFA-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MFA-021.

Explore the full profile